




RealRate

PHARMACEUTICAL 2022

Vaxxinity Inc
Rank 275 of 471

vaxxinity 



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Vaxxinity Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vaxxinity Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Vaxxinity Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 15% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	154,129
Cost of Goods Sold	1,937
Intangible Assets	0
Liabilities, Current	27,494
Liabilities, Non-Current	237
Other Assets	371
Other Compr. Net Income	0
Other Expenses	12,100
Other Liabilities	10,323
Other Net Income	0
Other Revenues	66
Property and Equipment	12,173
Research and Development	71,379
Selling, General and Administrative Expense	51,825

Output Variable	Value in 1000 USD
Assets	166,673
Liabilities	38,054
Expenses	137,241
Revenues	66
Stockholders Equity	128,619
Net Income	-137,175
Comprehensive Net Income	-137,175
BaseVar	171,017
ECR before Limited Liability	140%
Economic Capital Ratio	261%